292 related articles for article (PubMed ID: 31738958)
1. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
[TBL] [Abstract][Full Text] [Related]
2. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Wang Q; He WY; Zeng YZ; Hossain A; Gou X
Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
[TBL] [Abstract][Full Text] [Related]
4. KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy.
Jia J; Zhang HB; Shi Q; Yang C; Ma JB; Jin B; Wang X; He D; Guo P
Theranostics; 2019; 9(19):5464-5477. PubMed ID: 31534497
[TBL] [Abstract][Full Text] [Related]
5. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
6. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
[TBL] [Abstract][Full Text] [Related]
7. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
[No Abstract] [Full Text] [Related]
8. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling.
Lin C; Blessing AM; Pulliam TL; Shi Y; Wilkenfeld SR; Han JJ; Murray MM; Pham AH; Duong K; Brun SN; Shaw RJ; Ittmann MM; Frigo DE
Oncogene; 2021 Mar; 40(9):1690-1705. PubMed ID: 33531625
[TBL] [Abstract][Full Text] [Related]
9. Silencing forkhead box M1 promotes apoptosis and autophagy through SIRT7/mTOR/IGF2 pathway in gastric cancer cells.
Yu W; Cui X; Wan Z; Yu Y; Liu X; Jin L
J Cell Biochem; 2018 Nov; 119(11):9090-9098. PubMed ID: 29953672
[TBL] [Abstract][Full Text] [Related]
10. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells.
Cristofani R; Montagnani Marelli M; Cicardi ME; Fontana F; Marzagalli M; Limonta P; Poletti A; Moretti RM
Cell Death Dis; 2018 Aug; 9(9):889. PubMed ID: 30166521
[TBL] [Abstract][Full Text] [Related]
11. Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib.
Lyu X; Zeng L; Shi J; Ming Z; Li W; Liu B; Chen Y; Yuan B; Sun R; Yuan J; Zhao N; Yang X; Chen G; Yang S
J Exp Clin Cancer Res; 2022 Jun; 41(1):200. PubMed ID: 35690866
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
Hu F; Zhao Y; Yu Y; Fang JM; Cui R; Liu ZQ; Guo XL; Xu Q
Cancer Lett; 2018 Mar; 416():24-30. PubMed ID: 29246644
[TBL] [Abstract][Full Text] [Related]
13. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
14. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
Nguyen HG; Yang JC; Kung HJ; Shi XB; Tilki D; Lara PN; DeVere White RW; Gao AC; Evans CP
Oncogene; 2014 Sep; 33(36):4521-30. PubMed ID: 24662833
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.
Hamurcu Z; Delibaşı N; Nalbantoglu U; Sener EF; Nurdinov N; Tascı B; Taheri S; Özkul Y; Donmez-Altuntas H; Canatan H; Ozpolat B
J Mol Med (Berl); 2019 Apr; 97(4):491-508. PubMed ID: 30729279
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
18. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
Wang K; Zhu X; Zhang K; Zhu L; Zhou F
Acta Biochim Biophys Sin (Shanghai); 2016 Sep; 48(9):804-9. PubMed ID: 27521795
[TBL] [Abstract][Full Text] [Related]
19. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
20. Sympathetic β
Zhang M; Chen F; Sun X; Huang Y; Zeng Y; Chen J; Wu S; Xu C
Biochem Biophys Res Commun; 2023 May; 657():69-79. PubMed ID: 36989842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
